
Biodesix (BDSX) Stock Forecast & Price Target
Biodesix (BDSX) Analyst Ratings
Bulls say
Biodesix Inc. is anticipated to achieve robust financial performance, with projected revenue growth of 30% for 2026, driven primarily by a 32% increase in Lung Diagnostic Testing revenue. The company has demonstrated strong operational discipline and is well-capitalized, positioning it effectively to realize its expansion goals. Additionally, as the company plans to expand its sales force to approximately 120 representatives by the end of 2026, it is positioned to enhance its market reach and drive future revenue growth.
Bears say
Biodesix Inc. reported a revenue miss for the first quarter of 2025 and subsequently lowered its revenue guidance for the full year, primarily due to a shift in its commercial strategy. This strategic pivot indicates potential operational challenges and uncertainty regarding future revenue streams. Given these developments, the financial outlook appears concerning as reliance on contract-based services may expose the company to fluctuations in demand and revenue stability.
This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.
Biodesix (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares